Patents by Inventor Alberto Inga

Alberto Inga has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • High-fidelity CAS9 variants and applications thereof
    Patent number: 11525127
    Abstract: To address the limitations deriving from the unspecific genomic cleavages of the Streptococcus pyogenes Cas9 (SpCas9) and to identify variants with higher cleavage fidelity, the present invention describes a yeast-based assay which allows to simultaneously evaluate the on- and off-target activity towards two engineered genomic targets. The screening of SpCas9 variants obtained by random mutagenesis of the Red-II domain allowed the identification of hits with increased on/off ratios. The best performing nuclease, evoCas9, was isolated through the combination of the identified mutations within a single variant. Side by side analyses with previously reported rationally designed variants demonstrated a significant improvement in fidelity of evoCas9 of the present invention.
    Type: Grant
    Filed: February 14, 2018
    Date of Patent: December 13, 2022
    Assignee: UNIVERSITA' DEGLI STUDI DI TRENTO
    Inventors: Anna Cereseto, Antonio Casini, Gianluca Petris, Alberto Inga, Michele Olivieri
  • HIGH-FIDELITY CAS9 VARIANTS AND APPLICATIONS THEREOF
    Publication number: 20200149020
    Abstract: To address the limitations deriving from the unspecific genomic cleavages of the Streptococcus pyogenes Cas9 (SpCas9) and to identify variants with higher cleavage fidelity, the present invention describes a yeast-based assay which allows to simultaneously evaluate the on- and off-target activity towards two engineered genomic targets. The screening of SpCas9 variants obtained by random mutagenesis of the Red-II domain allowed the identification of hits with increased on/off ratios. The best performing nuclease, evoCas9, was isolated through the combination of the identified mutations within a single variant. Side by side analyses with previously reported rationally designed variants demonstrated a significant improvement in fidelity of evoCas9 of the present invention.
    Type: Application
    Filed: February 14, 2018
    Publication date: May 14, 2020
    Applicant: UNIVERSITA' DEGLI STUDI DI TRENTO
    Inventors: Anna CERESETO, Antonio CASINI, Gianluca PETRIS, Alberto INGA, Michele OLIVIERI
  • Human p53 mutations and a genetic system in yeast for functional identification of human p53 mutations
    Patent number: 7256260
    Abstract: The present invention provides isolated polypeptides of human p53 that contain mutations. These mutations can be toxic mutations, supertransactivating mutations or tox-suppressor mutations. Further provided by the invention are methods of identifying toxic, supertransactivating, weak transactivating and tox-suppressor mutations as well as methods of identifying compounds that mimic the toxic, supertransactivating and tox-suppressor mutations in human p53. Also provided are methods of inducing toxicity in a cell by administering a polypeptide comprising a supertransactivating or a toxic mutation.
    Type: Grant
    Filed: July 28, 2000
    Date of Patent: August 14, 2007
    Assignee: The United States of America, as represented by the Secretary, Dept. of Health and Human Services, NIH
    Inventors: Michael A. Resnick, Alberto Inga